Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Kono, Koji ^a,j   Iinuma, Hisae ^b   Akutsu, Yasunori ^c   Tanaka, Hiroaki ^d   Hayashi, Naoko ^e   Uchikado, Yasuto ^f   Noguchi, Tsuyoshi ^g   Fujii, Hideki ^a   Okinaka, Kota ^b   Fukushima, Ryoji ^b   Matsubara, Hisahiro ^c   Ohira, Masaichi ^d   Baba, Hideo ^e   Natsugoe, Shoji ^f   Kitano, Seigou ^g   Takeda, Kazuyoshi ^h   Yoshida, Koji ⁱ   Tsunoda, Takuya ⁱ   Nakamura, Yusuke ⁱ  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d Osaka Prefecture University   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f KAGOSHIMA UNIVERSITY   (Japan)

^g OITA UNIVERSITY   (Japan)

^h JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

more..

Author keywords

Cancer vaccine; Ctl; Esophageal cancer; Peptide vaccine; Phase ii clinical trial

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; FREUND ADJUVANT; HLA A ANTIGEN; INSULIN LIKE GROWTH FACTOR II MESSENGER RNA BINDING PROTEIN 3 VACCINE; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS K VACCINE; PEPTIDE VACCINE; TTK PROTEIN KINASE VACCINE; UNCLASSIFIED DRUG; PEPTIDE; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; ANTIGEN SPECIFICITY; ARTICLE; BLOOD TOXICITY; CANCER IMMUNIZATION; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS SURGERY; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HLA TYPING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; JAPAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; TREATMENT RESPONSE; AMINO ACID SEQUENCE; CANCER STAGING; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; VACCINATION;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MONITORING, IMMUNOLOGIC; NEOPLASM STAGING; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84863507258     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-141     Document Type: Article

References (26)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Impact study investigators. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. 10.1056/NEJMoa1001294, 20818862.
2. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008, 26:5950-5956. 10.1200/JCO.2008.16.1927, 19018089.
3. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127. 10.1056/NEJMoa1012863, 21631324.
4. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011, 29:2787-2794. 10.1200/JCO.2010.33.3005, 3139394, 21632504.
5. Cecco S, Muraro E, Giacomin E, Martorelli D, Lazzarini R, Baldo P, et al. Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. Curr Cancer Drug Targets 2011, 11:85-102. 10.2174/156800911793743664, 21062241.
6. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009, 100:1502-1509. 10.1111/j.1349-7006.2009.01200.x, 19459850.
7. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007, 98:1803-1808.
8. Yamabuki T, Daigo Y, Kato T, Hayama S, Tsunoda T, Miyamoto M, et al. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006, 28:1375-1384.
9. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007, 67:11601-11611. 10.1158/0008-5472.CAN-07-3243, 18089789.
10. Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006, 25:1456-1468. 10.1038/sj.emboj.7601039, 1440323, 16541107.
11. de Cárcer G, de Castro IP, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007, 14:969-985. 10.2174/092986707780362925, 17439397.
12. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008, 99:1448-1454. 10.1111/j.1349-7006.2008.00844.x, 18452554.
13. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996, 47:93-101. 10.1111/j.1399-0039.1996.tb02520.x, 8851721.
14. CLIA , Available from https://www.cms.gov/CLIA/05_CLIA_Brochures.asp.
15. ICH , Available from http://www.ich.org/products/guidelines.html.
16. Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 2012, 72:834-845. 10.1002/pros.21485, 21932426.
17. Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011, 29:2924-2932. 10.1200/JCO.2010.33.8053, 21690475.
18. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011, 253:328-335. 10.1097/SLA.0b013e3181fd271c, 3085934, 21217520.
19. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 29:330-336. 10.1200/JCO.2010.30.7744, 3056467, 21149657.
20. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011, 10:591-600. 10.1038/nrd3500, 21804596.
21. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005, 201:241-248. 10.1084/jem.20041379, 2212796, 15657293.
22. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138. 10.1097/00002371-200203000-00001, 12074049.
23. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011, 17:3064-3076. 10.1158/1078-0432.CCR-10-2234, 3096674, 21558394.
24. Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, et al. SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011, 9:155. 10.1186/1479-5876-9-155, 3189883, 21929757.
25. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006, 24:1612-1619. 10.1200/JCO.2005.03.4900, 16575012.
26. Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, et al. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. Int J Clin Oncol 2008, 13:150-155. 10.1007/s10147-007-0738-y, 18463960.